The metalloprotease ADAM17 in inflammation and cancer.
ADAM17
Cancer
IL-6
Inflammation
Proteolysis
TNFα
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
04
03
2019
revised:
05
04
2019
accepted:
05
04
2019
pubmed:
18
4
2019
medline:
11
1
2020
entrez:
18
4
2019
Statut:
ppublish
Résumé
Proteolytic cleavage of transmembrane proteins is an important post-translational modification that regulates the biological function of numerous transmembrane proteins. Among the 560 proteases encoded in the human genome, the metalloprotease A Disintegrin and Metalloprotease 17 (ADAM17) has gained much attention in recent years and has emerged as a central regulatory hub in inflammation, immunity and cancer development. In order to do so, ADAM17 cleaves a variety of substrates, among them the interleukin-6 receptor (IL-6R), the pro-inflammatory cytokine tumor necrosis factor α (TNFα) and most ligands of the epidermal growth factor receptor (EGFR). This review article provides an overview of the functions of ADAM17 with a special focus on its cellular regulation. It highlights the importance of ADAM17 to understand the biology of IL-6 and TNFα and their role in inflammatory diseases. Finally, the role of ADAM17 in the formation and progression of different tumor entities is discussed.
Identifiants
pubmed: 30992230
pii: S0344-0338(19)30358-9
doi: 10.1016/j.prp.2019.04.002
pii:
doi:
Substances chimiques
ADAM17 Protein
EC 3.4.24.86
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
152410Informations de copyright
Copyright © 2019 Elsevier GmbH. All rights reserved.